ストックスクリーナーアプリを入手
51.85
1.81%
0.92
アフターアワーズ：
50.05
-1.80
-3.47%
前日終値:
$50.93
開ける：
$51.25
24時間の取引高:
4.41M
Relative Volume:
1.63
時価総額：
$123.58B
収益：
$48.03B
当期純損益:
$6.06B
株価収益率:
20.75
EPS:
2.4983
ネットキャッシュフロー:
$9.91B
1週間 パフォーマンス:
+2.47%
1か月 パフォーマンス:
-8.88%
6か月 パフォーマンス:
-2.65%
1年 パフォーマンス:
+9.97%
1日の値動き範囲:
$51.25
$52.26
1週間の範囲:
$50.39
$52.26
52週間の値動き範囲:
$45.80
$60.12
Sanofi Adr Stock (SNY) Company Profile
SNY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SNY
Sanofi Adr
|
51.85 | 123.58B | 48.03B | 6.06B | 9.91B | 2.4983 |
|
LLY
Lilly Eli Co
|
827.54 | 743.27B | 45.04B | 10.59B | 414.30M | 11.71 |
|
JNJ
Johnson Johnson
|
157.75 | 371.98B | 89.33B | 21.81B | 18.06B | 8.99 |
|
ABBV
Abbvie Inc
|
173.78 | 312.76B | 56.33B | 4.28B | 17.83B | 2.40 |
|
NVO
Novo Nordisk Adr
|
59.91 | 286.27B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
111.41 | 217.12B | 51.72B | 11.94B | 13.81B | 5.88 |
Sanofi Adr Stock (SNY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-15 | 開始されました | Exane BNP Paribas | Outperform |
| 2025-03-21 | 開始されました | Goldman | Neutral |
| 2025-01-30 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-07-26 | 繰り返されました | Argus | Buy |
| 2024-01-23 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-01-16 | 再開されました | UBS | Buy |
| 2023-12-05 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2023-10-30 | ダウングレード | Stifel | Buy → Hold |
| 2023-09-06 | アップグレード | Berenberg | Hold → Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-04-28 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2023-03-27 | アップグレード | Barclays | Equal Weight → Overweight |
| 2022-12-13 | 再開されました | Morgan Stanley | Overweight |
| 2022-08-12 | アップグレード | Deutsche Bank | Sell → Hold |
| 2022-08-09 | ダウングレード | UBS | Buy → Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2021-09-27 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-01-15 | 開始されました | Deutsche Bank | Sell |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-03-17 | アップグレード | Barclays | Underweight → Equal Weight |
| 2020-03-11 | アップグレード | Goldman | Neutral → Buy |
| 2020-02-11 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-01-06 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-09-23 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-09-20 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-03 | 開始されました | Bernstein | Outperform |
| 2019-08-14 | アップグレード | UBS | Neutral → Buy |
| 2018-12-11 | アップグレード | Jefferies | Hold → Buy |
| 2018-11-01 | アップグレード | Barclays | Underweight → Equal Weight |
| 2018-10-09 | 開始されました | Guggenheim | Neutral |
| 2018-09-10 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2018-08-10 | アップグレード | Citigroup | Neutral → Buy |
| 2018-03-23 | アップグレード | Liberum | Hold → Buy |
| 2018-01-23 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2017-12-06 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2017-12-01 | ダウングレード | Morgan Stanley | Overweight → Underweight |
| 2017-11-15 | アップグレード | Barclays | Underweight → Equal Weight |
| 2017-08-30 | アップグレード | HSBC Securities | Reduce → Hold |
すべてを表示
Sanofi Adr (SNY) 最新ニュース
Meningococcal Vaccines Market Size to Surpass $9.05 Billion, Globally, by 2032 at 10.4% CAGR: Coherent Market Insights - GlobeNewswire Inc.
Communiqué de presse - GlobeNewswire Inc.
Futu Holdings ADR Clears Key Benchmark, Hitting 90-Plus RS Rating - inkl
European Equities Traded in the US as ADRs Fall in Tuesday Trading - MSN
Biotech Stocks To Watch And Pharma Industry News - Investor's Business Daily
LATAM Airlines Group ADR Clears Technical Benchmark, Hitting 90-Plus RS Rating - inkl
Is First Trust Value Line Dividend ETF (FVD) a Strong ETF Right Now? - Yahoo Finance
Led by Dupixent, Solid Immunology Position Helps Support Steady Long-Term Growth for Sanofi - Morningstar
4 healthcare stocks attractive on valuation and ESG risk - Morningstar
Can you achieve global diversification with multinational companies? - Morningstar
10 best US blue-chip shares to buy for the long term - Morningstar
Best international companies to own: 2023 Edition - Morningstar
Sanofi Inks $1.9B Deal With Dren Bio To Buy Autoimmune Disease Drug - Barchart.com
SNY Quantitative Stock Analysis - Nasdaq
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Top 3 International Names Offering High-Dividend Yields - TheStreet Pro
Bioengineered Protein Drugs Market Size to Cross USD 672.7 Billion by 2034, Growing at a CAGR of 6.2% - GlobeNewswire Inc.
European Equities Traded in the US as American Depositary Receipts Lower Wednesday - TradingView
Know Labs Inc (KNW) Stock: A Closer Look at the Market Potential - The News Heater
Piper Sandler Shows Market Leadership With Jump To 83 RS Rating - Inkl
Sanofi ADR Shows Market Leadership With Jump To 82 RS Rating - Investor's Business Daily
Gold Field ADR Sees Its Composite Rating Rise To 99 - Inkl
ZEEKR Intelligent ADR Shows Rising Price Performance With Jump To 80 RS Rating - Inkl
Validea Detailed Fundamental AnalysisSNY - Nasdaq
Harrow Earns Relative Strength Rating Upgrade - Inkl
Sanofi ADR Earns RS Rating Upgrade - Investor's Business Daily
Newmont Earns RS Rating Upgrade - Inkl
What was Skechers U S A, Inc (SKX)’s performance in the last session? - US Post News
Sanofi ADR (SNY) requires closer examination - US Post News
Sanofi ADR (SNY): A Technical Analysis - The News Heater
GNPX’s Market Whiplash: -38.94% YTD Decline, -42.28% Plunge in 30 Days - The InvestChronicle
Applied Materials Inc’s Banking’s 100-Day Moving Average at 182.60: Will the Stock Break Through? - The InvestChronicle
Sanofi Adr (SNY) 財務データ
収益
当期純利益
現金流量
EPS
2.22%
大文字化:
|
ボリューム (24 時間):